[go: up one dir, main page]

BR9809562A - Método de tratar doença de secura ocular com agonistas receptores purinérgicos - Google Patents

Método de tratar doença de secura ocular com agonistas receptores purinérgicos

Info

Publication number
BR9809562A
BR9809562A BR9809562-5A BR9809562A BR9809562A BR 9809562 A BR9809562 A BR 9809562A BR 9809562 A BR9809562 A BR 9809562A BR 9809562 A BR9809562 A BR 9809562A
Authority
BR
Brazil
Prior art keywords
triphosphate
purinergic receptor
subject
disclosed
methods
Prior art date
Application number
BR9809562-5A
Other languages
English (en)
Inventor
Benjamin R Yerxa
Karla M Jacobus
William Pendergast
Janet L Rideout
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25170925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9809562(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of BR9809562A publication Critical patent/BR9809562A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"MéTODO DE TRATAR DOENçA DE SECURA OCULAR COM AGONISTAS RECEPTORES PURINéRGICOS" Trata-se de um processo e preparação para a estimulação de secreção de lágrima em um sujeito em necessidade de tal tratamento são mostrados. O processo compreende administração às superfícies oculares do sujeito de um agonista de receptor purinérgico tal como uridina 5'-trifosfato [UTP], dinucleotídeos, citidina 5'-trifosfato [CTP], adenosina 5'-trifosfato [ATP], ou seus análogos e derivados terapeuticamente úteis, em uma quantidade efetiva para estimular secreção de fluido lágrima e aperfeiçoar drenagem do sistema lacrimal. Formulações farmacêuticas e processos de fabricação das mesmas também são mostrados. Processos de administração das mesmas podem incluir: administração tópica via um líquido, gel, creme ou coo parte de uma lente de contato ou membrana de liberação seletiva; ou administração sistêmica via gotas nasais ou spray, inalação por nebulizador ou outro dispositivo, forma oral (líquido ou pílula), injetável, instilação intra-operativa ou forma de supositório.
BR9809562-5A 1997-02-06 1998-02-06 Método de tratar doença de secura ocular com agonistas receptores purinérgicos BR9809562A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/797,472 US5900407A (en) 1997-02-06 1997-02-06 Method of treating dry eye disease with uridine triphosphates and related compounds
PCT/US1998/002701 WO1998034593A1 (en) 1997-02-06 1998-02-06 Method of treating dry eye disease with purinergic receptor agonists

Publications (1)

Publication Number Publication Date
BR9809562A true BR9809562A (pt) 2001-10-02

Family

ID=25170925

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809562-5A BR9809562A (pt) 1997-02-06 1998-02-06 Método de tratar doença de secura ocular com agonistas receptores purinérgicos

Country Status (19)

Country Link
US (6) US5900407A (pt)
EP (1) EP1003474B1 (pt)
JP (3) JP3652707B2 (pt)
KR (1) KR100378443B1 (pt)
CN (1) CN1151775C (pt)
AT (1) ATE428400T1 (pt)
AU (1) AU735684B2 (pt)
BR (1) BR9809562A (pt)
CA (1) CA2280183C (pt)
DE (1) DE69840746D1 (pt)
DK (1) DK1003474T3 (pt)
ES (1) ES2325892T3 (pt)
ID (1) ID23375A (pt)
MY (1) MY120023A (pt)
NO (1) NO329118B1 (pt)
NZ (1) NZ337405A (pt)
PT (1) PT1003474E (pt)
WO (1) WO1998034593A1 (pt)
ZA (1) ZA98979B (pt)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US6673779B2 (en) * 1996-03-27 2004-01-06 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6420347B1 (en) * 1997-03-27 2002-07-16 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6921755B2 (en) * 1998-02-06 2005-07-26 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US6696425B2 (en) * 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US7078391B2 (en) 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6596725B2 (en) 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
TW593331B (en) * 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
KR20010013797A (ko) * 1997-07-25 2001-02-26 인스파이어 파마슈티컬스 인코퍼레이티드 디(우리딘 5'-테트라포스페이트) 염 및 그의 제조방법과용도
US6548658B2 (en) * 1997-07-25 2003-04-15 Inspire Pharmaceuticals, Inc. Di-(uridine 5′)-tetraphosphate and salts thereof
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
WO1999061012A2 (en) * 1998-05-22 1999-12-02 Inspire Pharmaceuticals, Inc. Therapeutic dinucleotide and derivatives
EP1140967A1 (en) * 1998-12-23 2001-10-10 University Of North Carolina At Chapel Hill Targeted gene transfer using g protein coupled receptors
KR20010114214A (ko) * 1999-02-26 2001-12-31 인스파이어 파마슈티컬스 인코퍼레이티드 우리딘, 아데닌 및 시티딘 디포스페이트 및 그의 유사체에의한 점막수화 촉진방법
HU229225B1 (en) * 1999-06-30 2013-09-30 Inspire Pharmaceuticals Inc Raleigh Dinucleotide crystals
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6723737B1 (en) * 1999-10-20 2004-04-20 Eliezer Rapaport Methods, pharmaceutical and therapeutic compostions for administering adenosine
EP1221945A4 (en) * 1999-10-20 2005-06-15 Eliezer Rapaport METHOD AND PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS FOR THE ADMINISTRATION OF ADENOSINE
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6864243B1 (en) * 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
CA2413928C (en) 2000-05-30 2011-01-25 Santen Pharmaceutical Co., Ltd. Corneal epithelial migration promoter
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6555675B2 (en) 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
JP3945625B2 (ja) * 2001-03-30 2007-07-18 株式会社イーエムアイ 角膜上皮障害モデル動物及びそのモデル動物を用いた薬剤の評価方法並びにその評価方法を用いて選択された薬剤
US7629329B2 (en) 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
AR034635A1 (es) 2001-06-25 2004-03-03 Inspire Pharmaceuticals Inc Lubricacion de las articulaciones con agonistas del receptor purinergico p2y
CN1228053C (zh) * 2001-09-11 2005-11-23 参天制药株式会社 含有二尿苷磷酸的滴眼液
AU2002342672A1 (en) * 2001-09-11 2003-03-24 Nascacell Gmbh Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes
WO2003028712A2 (en) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
WO2003030893A1 (en) * 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue
WO2003030892A1 (en) * 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye
US20030109508A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
CA2465894A1 (en) * 2001-11-06 2003-05-15 Inspire Pharmaceuticals, Inc. Method for treating or preventing inflammatory diseases
US7084128B2 (en) * 2002-01-18 2006-08-01 Inspire Pharmaceuticals, Inc. Method for reducing intraocular pressure
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
US20060035811A1 (en) * 2002-10-18 2006-02-16 Luis Molina Methods of treating dry eye disease with lantibiotics
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
WO2005107787A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
EP1753445A4 (en) * 2004-05-06 2009-05-20 Molichem Medicines Inc TREATMENT OF EYE DISEASES AND EYE TREATMENTS WITH LANTIBIOTIC COMPOSITIONS
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
RU2287159C1 (ru) * 2005-03-14 2006-11-10 Уральская государственная медицинская академия дополнительного образования Способ прогнозирования течения синдрома "сухого глаза"
RU2271184C1 (ru) * 2005-06-02 2006-03-10 Федеральное государственное учреждение "Всероссийский центр глазной и пластической хирургии Федерального агентства по здравоохранению и социальному развитию" Способ хирургического лечения синдрома сухого глаза
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
CA2622975C (en) * 2006-01-27 2011-05-03 Can-Fite Biopharma Ltd. Adenosine a3 receptor agonists for the treatment of dry eye disorders
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090004244A1 (en) * 2007-06-27 2009-01-01 Orilla Werhner C Iris design as a drug depot for zonal drug delivery by contact lens
US20090004245A1 (en) * 2007-06-28 2009-01-01 Orilla Werhner C Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
EP2385839B1 (en) * 2009-01-09 2014-11-26 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of corneal disorders
EP2538965B1 (en) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
WO2011123180A1 (en) 2010-04-03 2011-10-06 Praful Doshi Medical devices including medicaments and methods of making and using same
PH12013500424B1 (en) * 2010-09-10 2018-07-11 Santen Pharmaceutical Co Ltd Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
US8918181B2 (en) 2010-11-16 2014-12-23 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
GEP20166448B (en) * 2010-12-28 2016-03-25 Santen Pharmaceutical Co Ltd Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate
EP3779598B1 (en) * 2011-04-06 2022-12-21 Kla-Tencor Corporation Method for providing a set of process tool correctables
TR201820073T4 (tr) 2012-03-26 2019-01-21 Santen Pharmaceutical Co Ltd Diquafosol içeren göz damlası.
US9717627B2 (en) 2013-03-12 2017-08-01 Oculeve, Inc. Implant delivery devices, systems, and methods
AU2014253754C1 (en) 2013-04-19 2015-07-30 Oculeve, Inc. Nasal stimulation devices and methods
EP3110405B1 (en) 2014-02-25 2020-05-06 Oculeve, Inc. Polymer formulations for nasolacrimal stimulation
ES2792856T3 (es) 2014-07-25 2020-11-12 Oculeve Inc Patrones de estimulación para tratar la sequedad ocular
WO2016065211A1 (en) 2014-10-22 2016-04-28 Oculeve, Inc. Contact lens for increasing tear production
US10207108B2 (en) 2014-10-22 2019-02-19 Oculeve, Inc. Implantable nasal stimulator systems and methods
BR112017008267A2 (pt) 2014-10-22 2017-12-19 Oculeve Inc dispositivos e métodos para tratar olho seco
US10729712B2 (en) 2015-06-05 2020-08-04 Santen Pharmaceutical Co., Ltd. Therapeutic agent for dry eye characterized by being applied to eye of dry eye patient wearing soft contact lens
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
AU2017260237A1 (en) 2016-05-02 2018-11-22 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
US10610095B2 (en) 2016-12-02 2020-04-07 Oculeve, Inc. Apparatus and method for dry eye forecast and treatment recommendation
TWI833406B (zh) 2018-02-28 2024-02-21 日商參天製藥股份有限公司 含有迪夸弗索（Ｄｉｑｕａｆｏｓｏｌ）及陽離子性聚合物之眼科用組合物
US20220054520A1 (en) 2019-02-27 2022-02-24 Santen Pharmaceutical Co., Ltd. Ophthalmic composition containing diquafosol or salt thereof, vinyl-based polymer and cellulose-based polymer
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2021039748A1 (ja) * 2019-08-27 2021-03-04 参天製薬株式会社 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物
KR20210110055A (ko) * 2020-02-28 2021-09-07 주식회사 종근당바이오 P1, p4-디(우리딘 5'-)테트라포스페이트 나트륨염 4 수화물 결정형 a의 제조방법
KR102548710B1 (ko) 2020-12-24 2023-06-28 주식회사 종근당 디쿠아포솔 또는 이의 약제학적으로 허용가능한 염과 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
JP2025528009A (ja) 2022-07-15 2025-08-26 ドーシ，プラフル 医薬品と薬剤などの不安定な構成要素の安定剤とを含むコンタクトレンズを作製及び使用する方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2330902A1 (de) * 1973-06-18 1975-03-20 Helmut Dr Med Zander Heilungsfoerderndes und vorbeugendes, zur aeusserlichen oertlichen anwendung auf der haut und im auge fuer mensch und tier bestimmtes arznei- bzw. hautpflegemittel
US4380239A (en) 1979-12-20 1983-04-19 The Hospital For Sick Children Intubation of lacrimal ducts
US4658816A (en) 1984-11-14 1987-04-21 Concept Incorporated Lighted canaliculus intubation sets
US4868154A (en) * 1986-02-19 1989-09-19 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with melanocyte stimulating hormones
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4921485A (en) 1988-09-28 1990-05-01 Griffiths John D Catheter for use in the surgical correction of a nasolacrimal duct obstruction
US5062831A (en) 1988-09-28 1991-11-05 Griffiths John D Catheter for use in the surgical correction of a nasolacrimal duct obstruction
US5021043A (en) 1989-09-11 1991-06-04 C. R. Bard, Inc. Method and catheter for dilatation of the lacrimal system
US5169386A (en) 1989-09-11 1992-12-08 Bruce B. Becker Method and catheter for dilatation of the lacrimal system
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5345948A (en) 1993-04-08 1994-09-13 Donnell Jr Francis E O Method of performing translactrimal laser dacryocystorhinostomy
WO1997035591A2 (en) * 1996-03-27 1997-10-02 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6921755B2 (en) 1998-02-06 2005-07-26 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US6696425B2 (en) 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
TW567456B (en) * 2001-02-15 2003-12-21 Au Optronics Corp Apparatus capable of improving flicker of thin film transistor liquid crystal display
FR2904554B1 (fr) * 2006-08-04 2010-11-05 Zheng Xu Lipides moleculaires heterogenes cytotropes (lmhc), procede de preparation, et methodes de traitement de patients porteurs de cancers multiples

Also Published As

Publication number Publication date
ATE428400T1 (de) 2009-05-15
NO993777L (no) 1999-10-05
US8097600B2 (en) 2012-01-17
MY120023A (en) 2005-08-30
JP5373576B2 (ja) 2013-12-18
US6887858B1 (en) 2005-05-03
KR20000070848A (ko) 2000-11-25
US20020103157A1 (en) 2002-08-01
JP2005015491A (ja) 2005-01-20
NO993777D0 (no) 1999-08-04
JP3652707B2 (ja) 2005-05-25
JP2010111676A (ja) 2010-05-20
DE69840746D1 (de) 2009-05-28
CA2280183A1 (en) 1998-08-13
JP2001504858A (ja) 2001-04-10
US20050197316A1 (en) 2005-09-08
NZ337405A (en) 2001-07-27
AU735684B2 (en) 2001-07-12
EP1003474A1 (en) 2000-05-31
NO329118B1 (no) 2010-08-30
AU6324198A (en) 1998-08-26
PT1003474E (pt) 2009-06-26
CA2280183C (en) 2008-04-22
DK1003474T3 (da) 2009-07-20
ES2325892T3 (es) 2009-09-23
US5900407A (en) 1999-05-04
HK1025915A1 (en) 2000-12-01
ID23375A (id) 2000-04-20
JP4664027B2 (ja) 2011-04-06
US6916794B2 (en) 2005-07-12
CN1151775C (zh) 2004-06-02
ZA98979B (en) 1999-02-19
WO1998034593A1 (en) 1998-08-13
US20080009463A1 (en) 2008-01-10
CN1250369A (zh) 2000-04-12
KR100378443B1 (ko) 2003-03-29
EP1003474B1 (en) 2009-04-15
US20100330164A1 (en) 2010-12-30
US7759322B2 (en) 2010-07-20
US7235535B2 (en) 2007-06-26

Similar Documents

Publication Publication Date Title
BR9809562A (pt) Método de tratar doença de secura ocular com agonistas receptores purinérgicos
MXPA01008547A (es) Metodo para promover la hidratacion de mucosas con ciertos difosfatos de uridina, adenina y citidina, y analogos de estos.
CA2250188A1 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
WO2001080844A3 (en) Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
AU2003287005B2 (en) Vaginal health products
NO996189L (no) FremgangsmÕte for fremstilling av di (uridin 5') - tetrafosfat) og salter derav i stor mÕlestokk
CA2259552A1 (en) Method of treating sinusitis with uridine triphosphates and related compounds
ATE225663T1 (de) Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln
IL122803A0 (en) Method fo detecting lung disease
KR920703041A (ko) 통증을 수반하는 염증성 또는 알레르기성 질환치료에 사용되는 성분물과 그 방법
BR0110418A (pt) Método para tratamento da degeneração retiniana com agonistas do receptor purinérgico
US7256183B2 (en) Method for treating or preventing inflammatory diseases
MXPA03006433A (es) Uso de polifosfato de dinucleosido para estimular la eliminacion de liquido en alteraciones retinales.
IT1254280B (it) Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson
ATE260118T1 (de) Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten
Lee et al. Nucleoside and nucleotide stimulation of fluid secretion in the pigmented rabbit conjunctiva
KR20000005404A (ko) 우리딘 트리포스페이트 및 관련 화합물로 섬모운동장해를치료하는 방법

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO UMA VEZ QUE O MESMO NAO ATENDE AO REQUISITO DE SUFICIENCIA DESCRITIVA ( ART. 24 DA LPI )

B12B Appeal against refusal [chapter 12.2 patent gazette]